Physician profile
Thomas Raulerson
NPI 1568486611
$2,816.15
in general payments reported to CMS, 2019-2025
29 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $224 · 2021: $769 · 2022: $415 · 2023: $564 · 2024: $324 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,277.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $756.29 | 2021-2025 | |
| Pfizer INC. | $356.96 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $247.48 | 2020-2024 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $193.40 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $147.14 | 2019-2022 | |
| Axsome Therapeutics, INC. | $118.32 | 2023-2025 | Sunosi, Auvelity |
| Orexo US, INC. | $111.22 | 2019-2021 | |
| Glaxosmithkline, LLC. | $83.89 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $76.75 | 2025 | Caplyta |
| Indivior INC. | $71.45 | 2024-2025 | Sublocade |
| Lilly USA, LLC | $70.31 | 2020-2023 | Mounjaro |
| Novo Nordisk INC | $67.34 | 2020-2021 | |
| Allergan, INC. | $53.46 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $52.83 | 2023 | Lyvispah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.15 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $47.54 | 2021 | |
| Ibsa Pharma INC. | $44.30 | 2024 | Tirosint, Licart |
| Alkermes, INC. | $43.09 | 2021-2022 | |
| Braeburn INC. | $37.89 | 2025 | Brixadi |
| Abbott Laboratories | $29.54 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $26.38 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $20.32 | 2022 | |
| Inspire Medical Systems, INC. | $19.79 | 2023 | Inspire |
| Hologic Sales and Service, LLC | $17.85 | 2019 | |
| Radius Health, INC. | $17.49 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.70 | 2021 | |
| Grifols USA, LLC | $14.91 | 2021 | |
| Kvk-Tech, INC. | $12.89 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Raulerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.